This study provided data to support that CofixRX Nasal Spray is 99.9% effective against SARS-CoV-2, 100% effective against Influenza B and RSV, and 94% effective against HRV-14. The combination of ingredients in CofixRX is highly virucidal against all four of the viruses tested in this laboratory analysis.
The laboratory analysis demonstrated that CofixRX achieved an LRV of 2.9+ 0.4, which indicates that 99.9% of the virus was killed after coming into contact with CofixRX for 45 seconds. Against influenza B, CofixRX achieved an LRV of > 5, indicating 100% effectiveness. CofixRX achieved an LRV of 1.2 against HRV-14, and an LRV > 2 against RSV. This translates to 94% effectiveness against HRV-14, which is associated with the common cold; effectiveness was 100% against RSV, which is an important cause of morbidity in the pediatric population.